156 related articles for article (PubMed ID: 20694904)
1. Bioethics and post-approval research in translational science.
Chen JY; Carter M
Am J Bioeth; 2010 Aug; 10(8):35-7. PubMed ID: 20694904
[No Abstract] [Full Text] [Related]
2. Post-approval translational research itself has diverse ethics.
Mukherjee J
Am J Bioeth; 2010 Aug; 10(8):43-4. PubMed ID: 20694908
[No Abstract] [Full Text] [Related]
3. Translational research beyond approval: a two-stage ethics review.
Sofaer N; Eyal N
Am J Bioeth; 2010 Aug; 10(8):W1-3. PubMed ID: 20694895
[No Abstract] [Full Text] [Related]
4. Rosiglitazone, marketing, and medical science.
Moynihan R
BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
[No Abstract] [Full Text] [Related]
5. Impediments to "T2" research: are ethics really to blame?
Lipworth W; Kerridge I
Am J Bioeth; 2010 Aug; 10(8):39-40. PubMed ID: 20694906
[No Abstract] [Full Text] [Related]
6. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
7. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
8. FDA puts restrictions on use of controversial diabetes drug.
Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
[No Abstract] [Full Text] [Related]
9. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
10. [Translational medicine].
Antal J; Timár A
Orv Hetil; 2011 Nov; 152(47):1894-902. PubMed ID: 22042316
[TBL] [Abstract][Full Text] [Related]
11. Keeping science on top in drug evaluation.
Avorn J
N Engl J Med; 2007 Aug; 357(7):633-5. PubMed ID: 17699813
[No Abstract] [Full Text] [Related]
12. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
13. Panel faults Pfizer in '96 clinical trial in Nigeria.
Stephens J
Washington Post; 2006 May; ():A1, A21. PubMed ID: 16718960
[No Abstract] [Full Text] [Related]
14. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
15. The diverse ethics of translational research.
Sofaer N; Eyal N
Am J Bioeth; 2010 Aug; 10(8):19-30. PubMed ID: 20694901
[TBL] [Abstract][Full Text] [Related]
16. Ethical analysis of translational research is more complex than distinguishing T1 from T2.
Allen B
Am J Bioeth; 2010 Aug; 10(8):33-5. PubMed ID: 20694903
[No Abstract] [Full Text] [Related]
17. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
18. Food and Drug Administration responds to pressure for expanded drug access.
Brower V
J Natl Cancer Inst; 2014 Jun; 106(6):dju171. PubMed ID: 24907387
[No Abstract] [Full Text] [Related]
19. Rosiglitazone and the FDA.
Krall RL
N Engl J Med; 2007 Oct; 357(17):1776-7; author reply 1777. PubMed ID: 17969232
[No Abstract] [Full Text] [Related]
20. After Avandia, some seek split in drug approval and monitoring.
Dolgin E
Nat Med; 2010 Aug; 16(8):831. PubMed ID: 20689527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
